心房颤动指南导向卒中预防治疗的依从性可实现
研究评估美国心脏协会Get With The Guidelines-AFIB登记中,CHA2DS2-VASc≥2的心房颤动患者口服抗凝药(OAC)处方对指南的依从性及时间趋势。结果显示出院时合格患者OAC处方率为93.5%,且随时间从79.9%提升至96.6%,证实指南推荐的高水平依从性可实现。
要点
- 出院时合格患者OAC处方率93.5%,排除严格禁忌后为80.3%。
- OAC处方率随时间显著改善,从79.9%升至96.6%。
- 入院时使用OAC与院内缺血性卒中调整后OR 0.38相关。
核心结论
- 在参与GWTG-AFIB质量改进计划的医院中,出院时合格患者OAC处方率显著提高并持续改善。
- 数据证实对指南推荐的卒中预防可实现高水平依从。
研究设计与样本
- 基于美国心脏协会Get With The Guidelines-AFIB登记的前瞻性队列分析。
主要发现
- 患者中位年龄73岁,女性占51%,中位CHA2DS2-VASc评分4分。
- 出院OAC处方率在年龄≤75岁、男性、心力衰竭、既往心房颤动消融及节律控制患者中更高(P<0.0001),西班牙裔患者最低(90.2%,P<0.0001)。
- 合格患者出院OAC处方率随时间从79.9%改善至96.6%(P<0.0001)。
临床怎么用
- 对CHA2DS2-VASc≥2的心房颤动患者,应遵循指南在出院时处方OAC以预防卒中。
- 关注西班牙裔等处方率较低人群,促进公平的指南依从。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efforts to improve prescription of oral anticoagulation (OAC) drugs in patients with atrial fibrillation have had limited success in improving guideline adherence. METHODS: We evaluated adherence to the American College of Cardiology/American Heart Association performance measures for OAC in eligible patients with a CHA2DS2-VASc score ≥2 and trends in prescription over time in the American Heart Association's Get With The Guidelines-AFIB (atrial fibrillation) registry. Adjusted associations with in-hospital outcomes were also determined. The cohort included 33 235 patients with a CHA2DS2-VASc score ≥2 who were admitted for atrial fibrillation and were enrolled at 115 sites between January 1, 2013, and September 31, 2017. RESULTS: The median (25th, 75th percentile) age was 73 years (65, 81 years); 51% were female; and the median (25th, 75th percentile) CHA2DS2-VASc score was 4 (3, 5). At admission, 16 206 (59.5%) of 27 221 patients with a previous diagnosis of atrial fibrillation were taking OAC agents, and OAC drug use at admission was associated with a lower adjusted odds of in-hospital ischemic stroke (odds ratio, 0.38; 95% CI, 0.24-0.59; P<0.0001). At discharge, prescription of OAC in eligible patients (no contraindications) was 93.5% (n=25 499 of 27 270). In a sensitivity analysis, when excluding only strict contraindications (4.6%, n=1497 of 32 806), OAC prescription at discharge was 80.3%. OAC prescription at discharge was higher in those aged ≤75 years, men, those with heart failure, those with previous atrial fibrillation ablation, and those with rhythm control ( P<0.0001 for all). OAC use was lowest in Hispanic patients (90.2%, P<0.0001). Prescription of OAC at discharge in eligible patients improved over time from 79.9% to 96.6% ( P<0.0001). CONCLUSIONS: Among hospitals participating in the GWTG-AFIB quality improvement program, OAC prescription at discharge in eligible guideline-indicated patients increased significantly and improved consistently over time. These data confirm that high-level adherence to guideline-recommended stroke prevention is achievable.
引用
- Piccini JP, Xu H, Cox M, et al. Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable. Circulation. 2019. PMID: 30700141. doi:10.1161/CIRCULATIONAHA.118.035909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。